Tempus AI to acquire Ambry Genetics
Nov. 5, 2024—Tempus AI announced it has entered into an agreement to acquire Ambry Genetics.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
CAP TODAY
FDA clears QIAstat-Dx meningitis/encephalitis panel
Nov. 4, 2024—Qiagen announced that the FDA has cleared the QIAstat-Dx Meningitis/Encephalitis panel for clinical use.
AML Express Testing: Leveraging Next-Generation Sequencing for Critical Gene Analysis
Given its aggressive nature and rapid progression, AML is considered an oncology emergency. Many AML treatment regimens depend on the expedited return of genetic test results to determine and initiate appropriate therapies. Download PDF.
Transforming Oncology with Illumina Genomics
Researchers from the Ontario Institute for Cancer Research and United Health Network share how knowing more about cancer biology through genomic studies is enabling universities and health systems to advance the fight against cancer. LEARN MORE.
Pillar gets CPT code for FDA-approved OncoReveal CDx kit
Oct. 24, 2024—Pillar Biosciences has announced it has been granted a unique CPT proprietary laboratory analyses code 0523U from the American Medical Association for its FDA-approved OncoReveal CDx pan-cancer solid tumor in vitro diagnostic NGS kit.
Astellas Vylox, Roche Ventana CDx approved for gastric cancer
Oct. 22, 2024—The FDA has approved zolbetuximab-clzb (Vyloy, Astellas Pharma), a claudin 18.2-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are CLDN18.2 positive, as determined by an FDA-approved test.
Qiagen white paper compares literature mining tool scores
Oct. 18, 2024—Qiagen published a white paper, titled “NIH Study Finds HGMD Professional Demonstrates a 126% Higher Precision Score than AI-derived Databases,” that discusses expert curation tools that help identify relevant literature for variant classification and the findings of a study conducted by investigators at the National Human Genome Research Institute.
Harm or help? Maternal AFP race adjustments
October 2024—Using a race adjustment in maternal serum alpha-fetoprotein screening has physicians sitting on the fence these days. Including race in calculating risk for open neural tube defects has been a longstanding practice in medicine. Adjusting for higher rates of AFP levels seen in Black pregnant patients, proponents say, allows this population to receive equitable care. That premise lies on one side of the fence. On the other are those who maintain the practice is suspect, even harmful, and that the routine use of a race-based adjustment should stop. With the experience of dropping raced-based adjustments to estimated glomerular filtration rates still fresh in many minds, physicians are now deciding whether to keep or drop the adjustment for maternal serum AFP, even ahead of any potential changes to guidance by groups such as the CAP. Little wonder. Because as anyone who has ever sat on a fence knows, it can easily become a shaky, even painful, perch.
Bio-Rad expands External Quality Assurance Services program
Oct. 17, 2024—Bio-Rad Laboratories has launched its External Quality Assurance Services specialty immunoassay program.
New system for hemolysis detection at point of care
October 2024—Werfen launched in July its Gem Premier 7000 with iQM3 blood gas testing system that for the first time makes hemolysis detection possible at the point of care. “Not having the capability to detect hemolysis at the point of care has been a gap in the field for quite a long time,” says Heather Stieglitz, PhD, D(ABCC).